Key Stats for Tilray Brands Stock
- Price Change for Tilray stock: 11%
- $TLRY Share Price as of Jan. 8: $9.13
- 52-Week High: $23.20
- $TLRY Share Price Target: $16.17
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Tilray (TLRY) stock jumped 11% in pre-market trading after the cannabis and consumer products company crushed Wall Street’s expectations for its fiscal second quarter.
The company posted a loss of $0.02 per share compared to analyst estimates for a 20-cent loss, while revenue came in at $217.5 million versus the $210.95 million consensus.
The beat marks Tilray’s highest-ever second-quarter revenue and continues a trend of improving fundamentals.
The company generated $8.4 million in adjusted EBITDA and $6 million in adjusted cash operating income while strengthening its balance sheet.
Tilray ended the quarter with approximately $292 million in cash and marketable securities and reduced debt by $4 million, moving from a net debt position to a net cash position of nearly $30 million.
The standout performer was international cannabis, which surged 36% year-over-year and 51% sequentially to $20 million.
CEO Irwin Simon emphasized that this momentum should continue as the company expands its global footprint across Europe, particularly in Germany, the U.K., and Poland. Total cannabis revenue reached $68 million for the quarter.
Canadian adult-use cannabis grew 6% year-over-year to $46 million, with Tilray shipping over 5.5 million units, its highest quarterly volume in two years.
The company also completed its first harvest from a restarted outdoor grow operation in Ontario, boosting annual cultivation capacity to 200 metric tons.
The Tilray Pharma distribution business posted its biggest quarter ever, growing 26% year-over-year to $85 million. Management expects to triple its medical cannabis distribution footprint in Germany during fiscal 2026 by leveraging the pharmacy network.
Tilray stock is down 33% in the past year. Despite the pullback, analysts remain bullish and expect TLRY stock surge 77%, given consensus price targets.
See analysts’ growth forecasts and price targets for Tilray stock (It’s free!) >>>
What the Market Is Telling Us About Tilray Stock
The strong reaction to Tilray stock reflects investor optimism about two major catalysts. First, President Trump’s decision to federally reschedule cannabis from Schedule I to Schedule III represents what Simon called “one of the most consequential regulatory shifts the industry has seen in decades.”
Tilray is positioning itself to capitalize immediately through its medical cannabis operations, which are already generating roughly $150 million annually across 20+ countries.
Second, the international cannabis growth trajectory is validating management’s strategy to redirect supply from lower-margin Canadian wholesale markets to higher-margin European markets.
During the quarter, Tilray deliberately scaled back Canadian wholesale sales and redeployed that supply internationally, a move that should continue driving margin improvement.
The beverage business remains a challenge, with revenue flat at $50 million amid ongoing headwinds in craft beer.
However, management reported $27 million in annualized cost savings in the first half and remains on track toward a $33 million savings target under “Project 420.” Spring product resets with retail partners, and new innovations are expected to drive revenue growth in the fourth quarter.
Despite the beverage struggles, Tilray stock investors appear focused on the cannabis opportunity. The company reaffirmed its full-year adjusted EBITDA guidance of $62 million to $72 million and emphasized its strong liquidity position as a strategic advantage in a rapidly evolving regulatory environment.
With improving profitability, a net cash balance sheet, and major global regulatory tailwinds, Tilray is positioning itself as a diversified cannabis, beverage, and wellness platform ready to scale.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Tilray Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
